Compare ADMA Biologics Inc (ADMA) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs L3Harris Technologies Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while L3Harris Technologies Inc trades at $291.88 (market cap $55.03B). The key difference: L3Harris Technologies Inc is far larger — about 25.8× ADMA Biologics Inc's market cap, and L3Harris Technologies Inc pays a 1.69% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | LHX | |
|---|---|---|
Market Cap | $2.13B | $55.03B |
Sector | Health | Industrials |
52-Week High | $20.38 | $378.48 |
52-Week Low | $7.60 | $257.09 |
Enterprise Value | $2.20B | $65.80B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
LHX trades at $295.4, down 2.21% today, with a bullish technical signal despite near-term overbought RSI conditions. The company reported strong Q1 2026 earnings, beating estimates with $5.7B revenue and a 1.4x book-to-bill ratio, boosting its backlog to a record $40.7B. Recent news highlights expansion in missile production and new defense contracts, supporting growth momentum.
LHX presents a favorable outlook with robust defense sector tailwinds and consistent earnings beats, though elevated valuation metrics and geopolitical risks warrant caution. Analyst consensus is strongly bullish with a $367.50 price target, implying significant upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
